Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161415 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
A Phase 1 study of Inflammation and Uveitis, sponsored by Quan Dong Nguyen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06161415: Recruiting Phase 1 study of Inflammation and Uveitis, sponsored by Quan Dong Nguyen.
NCT06161415 is a Phase 1 study of Inflammation and Uveitis that is actively recruiting participants, run by Quan Dong Nguyen. The registered enrollment target is 12 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161415, a Phase 1 study of Inflammation and Uveitis, is actively recruiting participants, sponsored by Quan Dong Nguyen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.
Primary Outcome
Assessment of concentration of Laquinimod in aqueous humor and vitreous samples of human by biolanalysis in specialized lab participants on Day 14 of Laquinimod eye-drop administration.
Conditions Studied
Interventions
- DRUG Laquinimod eye drops
Study Locations (1)
California
- Spencer Center for Vision Research at the Byers Eye Institute - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-05-03 |
| Est. Completion | 2025-07 |
| Phase | Phase 1 |
What NCT06161415 shows while recruiting
NCT06161415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Laquinimod eye drops is the first listed.
NCT06161415 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06161415 about?
NCT06161415 is a clinical study titled "Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study". The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.
What is the current status of trial NCT06161415?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-05-03. Estimated completion is 2025-07.
What conditions does trial NCT06161415 study?
This clinical trial studies the following conditions: Inflammation, Uveitis.
What interventions are being tested in trial NCT06161415?
The interventions under investigation include: Laquinimod eye drops (DRUG).
Who is sponsoring clinical trial NCT06161415?
This trial is sponsored by Quan Dong Nguyen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161415 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161415's enrollment target sits among peer trials
12 125th of 132 higher than 6 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
RECRUITING · Phase 1
-
Salt-Sensitivity and Immunity Cell Activation
ACTIVE NOT RECRUITING · Phase 1
-
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
COMPLETED · Phase 1
-
Flaxseed Modulates Inflammation and Oxidative Stress in CF
COMPLETED · Phase 1
-
Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
COMPLETED · Phase 1
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI